Skip to main content

Table 2 Number and share (%) of assessed and reimbursed orphan drugs by type of HTA recommendation, by country

From: The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe

Countrya Assessed orphan drugs (out of 101) Assessed orphan drugs Reimbursed orphan drugs
Positive Conditional Negative Assessed orphan drugs Not assessed orphan drugs
Total number Out of 101 Out of assessed drugs Positive Conditional Negative
England 20 % 20 60 % 12 5 % 1 35 % 7 13 13 % 65 % 25 % 3 0 % 0 14 % 1 11 % 9
Germany 25 % 25 100 % 25 0 % 0 0 % 0 20 20 % 80 % 76 % 19 0 % 0 0 % 0 1 % 1
Poland 36 % 36 19 % 7 36 % 13 44 % 16 23 23 % 64 % 71 % 5 69 % 9 31 % 5 6 % 4
Netherlands 38 % 38 13 % 5 74 % 28 13 % 5 30 30 % 79 % 20 % 1 75 % 21 40 % 2 10 % 6
Sweden 43 % 43 95 % 41 0 % 0 5 % 2 41 41 % 95 % 100 % 41 0 % 0 0 % 0 0 % 0
Scotland 60 % 61 51 % 31 2 % 1 48 % 29 11 11 % 18 % 19 % 6 0 % 0 10 % 3 5 % 2
Wales 67 % 68 28 % 19 9 % 6 63 % 43 13 13 % 19 % 32 % 6 0 % 0 12 % 5 6 % 2
France 74 % 75 85 % 64 9 % 7 5 % 4 20 20 % 27 % 30 % 19 0 % 0 25 % 1 0 % 0
  1. Source: Authors’ own calculations based on information from the websites of the eight HTA agencies
  2. Notes: aCountries ordered according to the share of assessed orphan drugs (from lowest to highest)